Relay Therapeutics Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Relay Therapeutics Inc. Common Stock trades at $17.46 (market cap $3.82B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 6.6× Relay Therapeutics Inc. Common Stock's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Relay Therapeutics Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| RLAY | RPRX | |
|---|---|---|
Market Cap | $3.82B | $25.27B |
Volume | 4,332,079 | 3,671,183 |
Sector | Health | Health |
52-Week High | $20.75 | $63.96 |
52-Week Low | $6.03 | $35.44 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.93B | $32.50B |
Dividend Yield | — | 1.66% |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →